Kiniksa Pharmaceuticals International (KNSA) Gross Profit (2021 - 2026)

Kiniksa Pharmaceuticals International's Gross Profit history runs 6 years deep, the most recent figure standing at $193.5 million for Q1 2026.

• Quarterly Gross Profit rose 61.34% year-over-year to $193.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $673.4 million (up 63.07% YoY) and the FY2025 annual result came in at $599.9 million, up 65.57% from the prior year.
• Gross Profit was $193.5 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $181.2 million in the prior quarter.
• Across five years, Gross Profit topped out at $193.5 million in Q1 2026 and bottomed at -$155.0 million in Q4 2022.
• A 5-year average of $81.5 million and a median of $92.1 million in 2024 frame the typical range for Gross Profit.
• Peak annual rise in Gross Profit reached 888.4% in 2022, while the deepest fall reached 1141.85% in 2022.
• Kiniksa Pharmaceuticals International's Gross Profit stood at -$155.0 million in 2022, then soared by 147.62% to $73.8 million in 2023, then jumped by 41.77% to $104.6 million in 2024, then surged by 73.15% to $181.2 million in 2025, then increased by 6.78% to $193.5 million in 2026.
• Business Quant data shows KNSA's Gross Profit at $193.5 million in Q1 2026, $181.2 million in Q4 2025, and $160.6 million in Q3 2025.